ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 131,41
0,69%
Dow Jones
39 035,03
0,39%
DAX
18 498,38
0,32%
Brent Oil
83,395
0,64%
Bitcoin
62 701,23
0,59%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Immunic Inc (IMUX)

  7. Immunic Inc (IMUX) Actualités

IMUX

Immunic (IMUX)

Immunic Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IMUX
DateHeureSourceTitreSymboleSociété
08/05/202413h20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMUXImmunic Inc
08/05/202412h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMUXImmunic Inc
08/05/202412h30PR Newswire (US)Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:IMUXImmunic Inc
06/05/202412h30PR Newswire (US)Immunic to Participate in Investor and Scientific Conferences in MayNASDAQ:IMUXImmunic Inc
01/05/202412h30PR Newswire (US)Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate UpdateNASDAQ:IMUXImmunic Inc
30/04/202412h30PR Newswire (US)Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & NeuroinflammationNASDAQ:IMUXImmunic Inc
04/04/202412h30PR Newswire (US)Immunic to Host MS R&D Day and Participate in Investor Conferences in AprilNASDAQ:IMUXImmunic Inc
20/03/202411h30PR Newswire (US)Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United StatesNASDAQ:IMUXImmunic Inc
07/03/202412h30PR Newswire (US)Immunic to Participate in Investor and Scientific Conferences in MarchNASDAQ:IMUXImmunic Inc
07/03/202403h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
29/02/202412h30PR Newswire (US)Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024NASDAQ:IMUXImmunic Inc
22/02/202412h38Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IMUXImmunic Inc
22/02/202412h30PR Newswire (US)Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate UpdateNASDAQ:IMUXImmunic Inc
15/02/202412h30PR Newswire (US)Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate UpdateNASDAQ:IMUXImmunic Inc
14/02/202422h05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMUXImmunic Inc
13/02/202422h36Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IMUXImmunic Inc
05/02/202414h30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:IMUXImmunic Inc
01/02/202412h30PR Newswire (US)Immunic to Participate in Investor and Scientific Conferences in FebruaryNASDAQ:IMUXImmunic Inc
24/01/202423h05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:IMUXImmunic Inc
19/01/202422h05Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:IMUXImmunic Inc
16/01/202422h12Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IMUXImmunic Inc
05/01/202412h35PR Newswire (US)Immunic Highlights 2023 Accomplishments and Upcoming MilestonesNASDAQ:IMUXImmunic Inc
05/01/202412h30PR Newswire (US)Immunic, Inc. Announces Private Placement of up to $240 MillionNASDAQ:IMUXImmunic Inc
21/11/202312h30PR Newswire (US)Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple SclerosisNASDAQ:IMUXImmunic Inc
14/11/202312h30PR Newswire (US)Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:IMUXImmunic Inc
07/11/202312h30PR Newswire (US)Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate UpdateNASDAQ:IMUXImmunic Inc
02/11/202311h30PR Newswire (US)Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its SaltsNASDAQ:IMUXImmunic Inc
26/10/202312h30PR Newswire (US)Immunic to Participate in Scientific and Industry Conferences in NovemberNASDAQ:IMUXImmunic Inc
16/10/202312h30PR Newswire (US)Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023NASDAQ:IMUXImmunic Inc
15/10/202312h30PR Newswire (US)Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023NASDAQ:IMUXImmunic Inc
 Showing the most relevant articles for your search:NASDAQ:IMUX

Dernières Valeurs Consultées

NYSE
NKE
Nike
COIN
BTCUSD
Bitcoin
EU
AI
Air Liquide
EU
RNO
Renault
EU
CAP
Capgemini
EU
PX1
CAC 40
EU
VK
Vallourec
NASDAQ
MSFT
Microsoft
EU
LR
Legrand
EU
ACA
Credit Agricole
EU
BNP
BNP Paribas
EU
CS
Axa
NASDAQ
GOOGL
Alphabet
EU
MC
Lvmh Moet Hennessy Louis...
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés